Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Uridine triphosphate

Drug Profile

Uridine triphosphate

Alternative Names: INS 316; INS 316 Diagnostic; KRN-316; Prolucin; UTP

Latest Information Update: 06 Jun 2007

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of North Carolina at Chapel Hill
  • Developer Inspire Pharmaceuticals; Kirin Brewery
  • Class Diagnostic agents; Expectorants; Nucleosides; Small molecules
  • Mechanism of Action Purinoceptor P2U agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Bronchitis; Cystic fibrosis; Lung cancer; Primary ciliary dyskinesia

Most Recent Events

  • 01 Jul 2003 Inspire is analysing phase III results with the aim to decide whether to terminate or continue the programme
  • 15 Nov 2001 A study has been added to the Diagnostic Agents therapeutic trials and adverse events sections
  • 28 Jun 2001 Genentech is no longer collaborating with Inspire Pharmaceuticals on pyrimidine Y2 agonist programmes
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top